1. Home
  2. BNGO vs QTTB Comparison

BNGO vs QTTB Comparison

Compare BNGO & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BNGO
  • QTTB
  • Stock Information
  • Founded
  • BNGO 2003
  • QTTB 2015
  • Country
  • BNGO United States
  • QTTB United States
  • Employees
  • BNGO N/A
  • QTTB N/A
  • Industry
  • BNGO Biotechnology: Laboratory Analytical Instruments
  • QTTB Biotechnology: Pharmaceutical Preparations
  • Sector
  • BNGO Industrials
  • QTTB Health Care
  • Exchange
  • BNGO Nasdaq
  • QTTB Nasdaq
  • Market Cap
  • BNGO 24.3M
  • QTTB 23.3M
  • IPO Year
  • BNGO 2018
  • QTTB N/A
  • Fundamental
  • Price
  • BNGO $3.88
  • QTTB $1.93
  • Analyst Decision
  • BNGO Buy
  • QTTB Hold
  • Analyst Count
  • BNGO 4
  • QTTB 8
  • Target Price
  • BNGO $7.67
  • QTTB $24.00
  • AVG Volume (30 Days)
  • BNGO 287.7K
  • QTTB 83.8K
  • Earning Date
  • BNGO 11-12-2025
  • QTTB 11-06-2025
  • Dividend Yield
  • BNGO N/A
  • QTTB N/A
  • EPS Growth
  • BNGO N/A
  • QTTB N/A
  • EPS
  • BNGO N/A
  • QTTB N/A
  • Revenue
  • BNGO $27,426,000.00
  • QTTB N/A
  • Revenue This Year
  • BNGO N/A
  • QTTB N/A
  • Revenue Next Year
  • BNGO $20.81
  • QTTB N/A
  • P/E Ratio
  • BNGO N/A
  • QTTB N/A
  • Revenue Growth
  • BNGO N/A
  • QTTB N/A
  • 52 Week Low
  • BNGO $2.68
  • QTTB $1.35
  • 52 Week High
  • BNGO $30.52
  • QTTB $53.17
  • Technical
  • Relative Strength Index (RSI)
  • BNGO 51.09
  • QTTB 55.02
  • Support Level
  • BNGO $3.55
  • QTTB $1.62
  • Resistance Level
  • BNGO $5.50
  • QTTB $1.81
  • Average True Range (ATR)
  • BNGO 0.45
  • QTTB 0.15
  • MACD
  • BNGO 0.01
  • QTTB 0.02
  • Stochastic Oscillator
  • BNGO 16.92
  • QTTB 65.96

About BNGO Bionano Genomics Inc.

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.

About QTTB Q32 Bio Inc. Common Stock

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Share on Social Networks: